A WEGO Health white paper examined how the change could affect patient influencers.
Novo Nordisk diabetes pill delivers in late-stage trial; Gilead partners with Sangamo on engineered cell therapies; Study finds antidepressants work, though with varying results.
Dohmen will continue to operate under its brand and retain its leadership team.
The new HHS secretary has been given a difficult task by President Trump: bring drug prices down.
AbbVie reports successful elagolix trial; White House touts short-term insurance plans; Mayo Clinic chief to retire.
Talukdar will lead the firm's advisory practice, VantageRx.
Gilead wins reversal of $2.5 billion payment order; Aimmune Therapeutics' peanut allergy therapy shows promise; AstraZeneca wins FDA approval on key cancer drug.
Roche to acquire Flatiron Health for $1.9B; FDA considers allowing pre-symptom Alzheimer's drug tests; Marijuana producer branches into pharma.
The agency began working with the national reproductive center this month.
CMS forecasts prescription drug spending to hit $5.7T by 2026; Ipsen predicts cancer drug shopping spree; Omnicom numbers miss estimates on revenue.
The two organizations will partner on content including personal stories and expert advice.
In 2017, Interpublic reported a net income of $579 million, down 4.8% from the previous year.
IPG 2017 net income drops; Bristol-Myers Squibb inks $1.85 billion deal with Nektar on cancer drug; Merck halts final-stage Alzheimer's drug.
Daniel Carucci is joining the Interpublic Group firm full-time after serving as a consultant and in roles with the U.N. Foundation and the U.S. Navy.
The company is also looking to better combine its web and social media presence.